1. Clinical outcome of germ cell cancer patients (pts) treated with high-dose chemotherapy with stem cell support (HDC) –a single center experience
- Author
-
Ana Vera Machado, Nuno Miranda, André Raimundo Guimarães, Manuel Abecasis, Isabel C.F.R. Ferreira, E. G. Dos Santos, José Luís Passos-Coelho, and F. Leal-da-Costa
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,macromolecular substances ,ThioTEPA ,Single Center ,chemistry.chemical_compound ,Internal medicine ,otorhinolaryngologic diseases ,medicine ,Etoposide ,Chemotherapy ,Ifosfamide ,business.industry ,Carboplatin ,Surgery ,carbohydrates (lipids) ,stomatognathic diseases ,Germ cell cancer ,chemistry ,bacteria ,High-Dose Chemotherapy with Stem Cell Support ,business ,medicine.drug - Abstract
4724 Background: Pts with International Germ Cell Cancer Collaborative Group (IGCCCG) “poor prognosis” disease achieve only a 41% 5-year progression-free survival (PFS) with standard chemotherapy. Pts who do not achieve a complete remission with BEP chemotherapy or who relapse after such treatment have a still worse prognosis. The clinical impact of HDC in such pts is still unclear. Methods: Pts with germ cell cancer with IGCCCCG “poor prognosis” disease at diagnosis (or, earlier, with Indiana group C) or with recurrent or refractory (i.e., less than marker negative partial remission) disease after initial BEP chemotherapy were eligible for HDC. Results: Between June 1996 and April 2003, 18 pts underwent one (13 pts) or two (5 pts) cycles of HDC with ICE (ifosfamide 10g/m2, carboplatin 1,500mg/m2 and etoposide 2,400mg/m2); 17 pts), or etoposide (1500mg/m2) plus thiotepa (900 mg/m2); 1 pt), in 6 pts as consolidation after BEP and in 12 pts for recurrent disease (7 pts) or refractoriness to BEP (5 pts). In ...
- Published
- 2004
- Full Text
- View/download PDF